利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

325 条记录 (耗时 0.029 秒)

    Ameliorant for hepatitis C therapeutic effect and application thereof
    31.
    发明授权
    Ameliorant for hepatitis C therapeutic effect and application thereof 失效
    改善丙型肝炎治疗效果及其应用

    公开(公告)号：US06455051B1

    公开(公告)日：2002-09-24

    申请号：US09529303

    申请日：2000-04-12

    申请人： Norio Hayashi ,  Yuji Kito ,  Aya Furukawa

    发明人： Norio Hayashi ,  Yuji Kito ,  Aya Furukawa

    IPC分类号： A61K3929

    CPC分类号： A61K38/21 ,  A61K38/217 ,  Y10S514/894 ,  A61K2300/00

    摘要： The present invention provides an ameliorant for enhancing the therapeutic effect of IFN-&agr; on hepatitis C; a therapeutic composition for the treatment of hepatitis C which comprises IFN-&agr; and IFN-&ggr; as active ingredients and further contains a pharmaceutically acceptable carrier; a kit for the treatment of hepatitis C which comprises an IFN-&agr; preparation and an IFN-&ggr; preparation; and a therapeutic method for the treatment of hepatitis C which comprises administering IFN-&agr; and IFN-&ggr; to a subject at the same time or administering IFN-&ggr; before the administration of IFN-&agr;. The present invention is capable of making the patient continuously HCV-RNA negative and is extremely useful in the treatment of chronic hepatitis C which is intractable with, IFN-&agr; and conventionally difficult to remedy.

    摘要翻译： 本发明提供了用于增强IFN-α对丙型肝炎的治疗效果的改善剂; 用于治疗丙型肝炎的治疗组合物，其包含IFN-α和IFN-γ作为活性成分，并且还含有药学上可接受的载体; 用于治疗丙型肝炎的试剂盒，其包含IFN-α制剂和IFN-γ制剂; 以及用于治疗丙型肝炎的治疗方法，其包括在施用IFN-α之前同时向受试者施用IFN-α和IFN-γ或在施用IFN-γ之前施用IFN-γ。 本发明能够使患者连续HCV-RNA阴性，并且在治疗与IFN-α难以治疗的常规难以治疗的慢性丙型肝炎方面非常有用。

    Herbal compositions for hepatic disorders
    32.
    发明授权
    Herbal compositions for hepatic disorders 失效
    肝脏疾病的草药组合物

    公开(公告)号：US06426098B1

    公开(公告)日：2002-07-30

    申请号：US09679400

    申请日：2000-10-03

    申请人： Yi Fan Yang Jr.

    发明人： Yi Fan Yang Jr.

    IPC分类号： A61K3578

    CPC分类号： A61K36/00 ,  A61K36/07 ,  A61K36/537 ,  Y02A50/463 ,  Y10S514/893 ,  Y10S514/894 ,  A61K2300/00

    摘要： Compositions for treating hepatic disorders via oral or parenteral administration include Salvia miltiorrhiza and Polyporus umbellatus in proportions of about 1:1 to about 5:1, and may comprise from about 6% to about 30% of the total weight of the composition which may also include other herbs such as Curcuma longa, Astragalus membranaceus, Loranthus parasiticus and Polygonum cuspidatum.

    摘要翻译： 用于通过口服或肠胃外给药治疗肝脏疾病的组合物包括比例为约1:1至约5:1的丹参和多孔多形菌，并且可以占组合物总重量的约6％至约30％ 包括其他草药如姜黄，黄芪，紫草，枸杞。

    Combination therapy for chronic hepatitis C infection
    34.
    发明授权
    Combination therapy for chronic hepatitis C infection 失效
    慢性丙型肝炎感染的联合治疗

    公开(公告)号：US06387365B1

    公开(公告)日：2002-05-14

    申请号：US08444584

    申请日：1995-05-19

    申请人： Janice K. Albrecht ,  Paul C. Grint

    发明人： Janice K. Albrecht ,  Paul C. Grint

    IPC分类号： A61K3821

    CPC分类号： A61K38/212 ,  Y10S514/885 ,  Y10S514/894 ,  A61K31/70 ,  A61K2300/00

    摘要： There is disclosed a method for treating chronic hepatitis C infection in patients in need of such treating comprising administering an amount of alpha interferon in association with an amount of ribavirin effective to treat chronic hepatitis C infection with the absence or substantial reduction of side effects associated with administration of ribavirin and alpha interferon.

    摘要翻译： 公开了一种在需要这种治疗的患者中治疗慢性丙型肝炎感染的方法，包括给予一定量的α干扰素与一定量的有效治疗慢性丙型肝炎感染的利巴韦林相关联，不存在或显着降低与 施用利巴韦林和α干扰素。

    ORAL IMMUNOLOGY USING PLANT PRODUCT CONTAINING A NON-ENTERIC PATHOGEN ANTIGEN
    35.
    发明申请
    ORAL IMMUNOLOGY USING PLANT PRODUCT CONTAINING A NON-ENTERIC PATHOGEN ANTIGEN 有权
    使用含有非肠道病原体抗原的植物产品的口腔免疫

    公开(公告)号：US20020004076A1

    公开(公告)日：2002-01-10

    申请号：US09464414

    申请日：1999-12-16

    发明人： YASMIN THANAVALA

    IPC分类号： A61K035/78 ,  A61K045/00

    CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/292 ,  A61K2039/5156 ,  A61K2039/542 ,  A61K2039/55544 ,  C12N15/8258 ,  C12N2730/10122 ,  C12N2730/10134 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/40 ,  Y02A50/403 ,  Y02A50/407 ,  Y02A50/472 ,  Y10S514/894

    摘要： A method for obtaining an immune response to a non-enteric pathogen antigen (NEPA) such as hepatitis B surface antigen (HBsAg) by feeding the antigen in a plant material to an animal that is immunoreceptive to the NEPA. It has now been discovered that the animal may be made immunoreceptive to the NEPA such as HBsAg by prior primary immunization. When the animal is made immunoreceptive by a prior, e.g. primary, immunization, an immune response to the NEPA may be boosted in the animal by feeding the animal the plant material containing the NEPA. For example, an animal, e.g. a human, that previously had a positive response to primary immunization against hepatitis B, can have a booster response to HBsAg by feeding the animal the antigen in a plant material. The plant material is a substance comprising a physiologically acceptable plant material, especially potatoes, containing the NEPA, e.g. hepatitis B surface antigen (HBsAg). The NEPA, e.g. HBsAg in the plant results from expression by the plant of the NEPA due to genetic alteration.

    摘要翻译： 通过将植物材料中的抗原喂养到对NEPA免疫接受的动物，获得对非肠道病原体抗原（NEPA）如乙型肝炎表面抗原（HBsAg）的免疫应答的方法。 现在已经发现，通过先前的初次免疫，可以使动物对NEPA例如HBsAg免疫接种。 当动物由先前的，例如， 原发性，免疫，对NEPA的免疫应答可以通过向动物喂养含有NEPA的植物材料来增强动物的免疫应答。 例如，动物，例如， 以前对乙型肝炎初次免疫有正面反应的人可以通过将动物的抗原喂养在植物材料中而对HBsAg具有加强反应。 植物材料是包含生理上可接受的植物材料，特别是包含NEPA的土豆的物质，例如， 乙型肝炎表面抗原（HBsAg）。 NEPA，例如 植物中的HBsAg由于遗传改变而由NEPA植物的表达产生。

    5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
    36.
    发明授权
    5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon 失效
    利巴韦林的5'-氨基酸酯及其用途用干扰素治疗丙型肝炎

    公开(公告)号：US06277830B1

    公开(公告)日：2001-08-21

    申请号：US09348534

    申请日：1999-07-07

    申请人： Ashit K. Ganguly ,  Jinping McCormick ,  Raymond G. Lovey ,  Frank Bennett ,  Anil K. Saksena ,  Viyyoor M. Girijavallabhan

    发明人： Ashit K. Ganguly ,  Jinping McCormick ,  Raymond G. Lovey ,  Frank Bennett ,  Anil K. Saksena ,  Viyyoor M. Girijavallabhan

    IPC分类号： A01N4304

    CPC分类号： C07H19/056 ,  Y10S514/894

    摘要： 5′-Amino acid esters of ribavirin represented by formula I: wherein R is CH3CH(NH2)—CO—, CH3CH2(CH3)CHCH(NH2)—CO—or H2N(CH2)4CH(NH2)—CO—; preferably R is or a pharmaceutically acceptable salt thereof, e.g., trifluoroacetate, tosylate, mesylate, and chloride, pharmaceutical compositions containing them as well as methods of treating patients having susceptible viral infections, e.g., chronic hepatitis C infections by administering a therapeutically effective amount of a ribavirin derivative, alone or in combination with a therapeutically effective amount of interferon-alpha are disclosed.

    摘要翻译： 由式I表示的利巴韦林的氨基酸酯：其中R是CH 3 CH（NH 2）-CO-，CH 3 CH 2（CH 3）CHCH（NH 2）-CO-或H 2 N（CH 2）4 CH（NH 2）-CO-; 优选R是其药学上可接受的盐，例如三氟乙酸盐，甲苯磺酸盐，甲磺酸盐和氯化物，含有它们的药物组合物以及治疗患有易感病毒感染的患者的方法，例如慢性丙型肝炎感染，通过施用治疗有效量的 公开了单独或与治​​疗有效量的干扰素-α组合的利巴韦林衍生物。

    Hepatoprotective compositions and composition for treatment of conditions related to hepatitis B and E infection
    39.
    发明授权
    Hepatoprotective compositions and composition for treatment of conditions related to hepatitis B and E infection 失效
    用于治疗与乙型和丙型肝炎感染有关的病症的肝保护组合物和组合物

    公开(公告)号：US6136316A

    公开(公告)日：2000-10-24

    申请号：US843709

    申请日：1997-04-16

    申请人： Raj Mehrotra ,  Chandra Kant Katiyar ,  Ajaya Prakash Gupta

    发明人： Raj Mehrotra ,  Chandra Kant Katiyar ,  Ajaya Prakash Gupta

    IPC分类号： A61K9/20 ,  A61K9/48 ,  A61K36/00 ,  A61K36/48 ,  A61K35/78

    CPC分类号： A61K36/00 ,  A61K36/48 ,  Y10S514/893 ,  Y10S514/894 ,  Y10S514/962

    摘要： The invention provides a novel polyherbal composition useful for treating acute Hepatitis E virus infection including acute liver failure due to HEV infection, healthy Hepatitis B virus carriers who develop superadded hepatitis E virus infection, acute hepatitis B virus infection, and animal hepadna virus, therapeutic effects on hepatitis B virus infection and also used as a hepatoprotective agent, said composition comprising essentially extracts of plants Rheum emodi Wall., Phyllanthus amarus Linn., Eclipta alba Hassk., Andrographis paniculate Nees., and Picrorhiza kurroa Royle ex Benth., and optionally Fumaria officinalis, Tinospora cordifolia Miers., Terminalia chebula Retz., Cichorium intybus Linn., Tephrosea purpurea Linn. and Boerhaavia diffusa Linn.

    摘要翻译： 本发明提供了一种用于治疗急性戊型肝炎病毒感染的新型多巴耳组合物，包括HEV感染引起的急性肝衰竭，发展超级戊型肝炎病毒感染的健康乙型肝炎病毒携带者，急性乙型肝炎病毒感染和动物肝炎病毒，治疗效果 对乙型肝炎病毒感染并且还用作肝保护剂，所述组合物基本上包含植物的提取物大黄素，叶螨，Eclipta alba Hassk。，Andrographis paniculate Nees。和Picrorhiza kurroa Royle ex Benth。 Fumaria officinalis，Tinospora cordifolia Miers。，Terminalia chebula Retz。，Cichorium intybus Linn。，Tephrosea purpurea Linn。 和Boerhaavia diffusa Linn。

    Method for treating and improving diabetes
    40.
    发明授权
    Method for treating and improving diabetes 失效
    治疗和改善糖尿病的方法

    公开(公告)号：US5981510A

    公开(公告)日：1999-11-09

    申请号：US60381

    申请日：1998-04-15

    申请人： Michio Fujiwara ,  Seisuke Inada ,  Yoshiharu Matahira ,  Shigehiro Kaneko

    发明人： Michio Fujiwara ,  Seisuke Inada ,  Yoshiharu Matahira ,  Shigehiro Kaneko

    IPC分类号： A61K31/715 ,  A01N43/04

    CPC分类号： A61K31/715 ,  Y10S514/893 ,  Y10S514/894

    摘要： A method for treating and improving diabetes and liver dysfunction, can be obtained by administering at least one selected from a chitin oligosaccharide, a chitosan oligosaccharide and salts thereof, in an effective amount. As the chitin oligosaccharide, preferred is one having the degree of polymerization of from 2 to 7. As the chitosan oligosaccharide, preferred is one having the degree of polymerization of from 2 to 8. As the method for administration, it is preferred to add them to e.g. foods, medicines or feeds, and orally ingest them. However, when used as medicines, administration methods such as intravenous injection and muscular injection, may be used.

    摘要翻译： 治疗和改善糖尿病和肝功能障碍的方法可以通过以有效量施用选自壳多糖寡糖，壳聚糖寡糖及其盐中的至少一种来获得。 作为几丁质寡糖，优选聚合度为2〜7的聚对苯二甲酸二糖。作为壳聚糖寡糖，优选聚合度为2〜8的聚糖。作为给药方法，优选添加 到例如 食品，药品或饲料，并口服摄取。 然而，当用作药物时，可以使用静脉内注射和肌肉注射等施用方法。